FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793173935> ?p ?o ?g. }

• W2793173935 endingPage "520" @default.
• W2793173935 startingPage "513" @default.
• W2793173935 abstract "Erlotinib is approved for the treatment of patients with EGFR mutation positive, metastatic NSCLC. It is also approved as second/third line therapy for EGFR mutation negative patients, but in this setting the benefit of erlotinib is modest and there is no validated biomarker for selecting EGFR wild-type patients who may benefit the most from the treatment. We retrospectively assessed EGFR and K-RAS mutational status, and EGFR, c-MET and IGF1-R expression in tumor samples of 72 patients with metastatic NSCLC treated with erlotinib after at least one prior line of chemotherapy, from 2008 to 2012. We analyzed the association between biomarkers and outcome (RR, PFS, and OS). EGFR mutated patients achieved a better RR (56% vs 8%, p = .002), PFS (10 vs 3 months, HR 0.53, p = 0.48) and OS (20 vs 6 months, HR 0.55, p = .07), compared to EGFR wild-type patients. Among 63 EGFR wild-type patients, those with EGFR high-expression had a better outcome in terms of RR (40% vs 2%, p = .002), PFS (7.5 vs 2 months, HR 0.45, p = .007) and OS (30 vs 5 months, HR 0.34, p < .001) compared to patients with EGFR intermediate or low/negative-expression. IGF1-R expression, c-MET expression and K-RAS mutational status did not significantly affect the outcome; however, no patients with K-RAS mutation or c-MET high-expression achieved an objective response. In patients with metastatic, chemo-refractory EGFR wild-type NSCLC, EGFR high-expression may represent a positive predictor of activity for erlotinib, whereas K-RAS mutation and c-MET high-expression may predict lack of activity. These findings deserve further prospective evaluation." @default.
• W2793173935 created "2018-03-29" @default.
• W2793173935 creator A5004635457 @default.
• W2793173935 creator A5006457492 @default.
• W2793173935 creator A5011458340 @default.
• W2793173935 creator A5042730999 @default.
• W2793173935 creator A5043302833 @default.
• W2793173935 creator A5053082535 @default.
• W2793173935 creator A5066923986 @default.
• W2793173935 creator A5073186349 @default.
• W2793173935 creator A5075562434 @default.
• W2793173935 creator A5080721675 @default.
• W2793173935 creator A5089173622 @default.
• W2793173935 date "2018-03-20" @default.
• W2793173935 modified "2023-09-30" @default.
• W2793173935 title "Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis" @default.
• W2793173935 cites W1948677875 @default.
• W2793173935 cites W1982488143 @default.
• W2793173935 cites W2008550599 @default.
• W2793173935 cites W2020600748 @default.
• W2793173935 cites W2029740942 @default.
• W2793173935 cites W2030132001 @default.
• W2793173935 cites W2035390137 @default.
• W2793173935 cites W2042581859 @default.
• W2793173935 cites W2055030390 @default.
• W2793173935 cites W2055080028 @default.
• W2793173935 cites W2063247623 @default.
• W2793173935 cites W2074829544 @default.
• W2793173935 cites W2096198395 @default.
• W2793173935 cites W2097026987 @default.
• W2793173935 cites W2099071272 @default.
• W2793173935 cites W2104347254 @default.
• W2793173935 cites W2105026490 @default.
• W2793173935 cites W2106787323 @default.
• W2793173935 cites W2107304950 @default.
• W2793173935 cites W2110540279 @default.
• W2793173935 cites W2111662961 @default.
• W2793173935 cites W2120930418 @default.
• W2793173935 cites W2132157071 @default.
• W2793173935 cites W2138297714 @default.
• W2793173935 cites W2138604360 @default.
• W2793173935 cites W2144897519 @default.
• W2793173935 cites W2146346695 @default.
• W2793173935 cites W2156353875 @default.
• W2793173935 cites W2159578294 @default.
• W2793173935 cites W2166649051 @default.
• W2793173935 cites W2199220147 @default.
• W2793173935 cites W2256274387 @default.
• W2793173935 cites W2527905628 @default.
• W2793173935 cites W2560367415 @default.
• W2793173935 cites W2567746986 @default.
• W2793173935 cites W2572174216 @default.
• W2793173935 cites W4256695226 @default.
• W2793173935 doi "https://doi.org/10.1007/s12253-018-0404-x" @default.
• W2793173935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29557085" @default.
• W2793173935 hasPublicationYear "2018" @default.
• W2793173935 type Work @default.
• W2793173935 sameAs 2793173935 @default.
• W2793173935 citedByCount "5" @default.
• W2793173935 countsByYear W27931739352019 @default.
• W2793173935 countsByYear W27931739352020 @default.
• W2793173935 countsByYear W27931739352021 @default.
• W2793173935 countsByYear W27931739352022 @default.
• W2793173935 countsByYear W27931739352023 @default.
• W2793173935 crossrefType "journal-article" @default.
• W2793173935 hasAuthorship W2793173935A5004635457 @default.
• W2793173935 hasAuthorship W2793173935A5006457492 @default.
• W2793173935 hasAuthorship W2793173935A5011458340 @default.
• W2793173935 hasAuthorship W2793173935A5042730999 @default.
• W2793173935 hasAuthorship W2793173935A5043302833 @default.
• W2793173935 hasAuthorship W2793173935A5053082535 @default.
• W2793173935 hasAuthorship W2793173935A5066923986 @default.
• W2793173935 hasAuthorship W2793173935A5073186349 @default.
• W2793173935 hasAuthorship W2793173935A5075562434 @default.
• W2793173935 hasAuthorship W2793173935A5080721675 @default.
• W2793173935 hasAuthorship W2793173935A5089173622 @default.
• W2793173935 hasConcept C104317684 @default.
• W2793173935 hasConcept C121608353 @default.
• W2793173935 hasConcept C126322002 @default.
• W2793173935 hasConcept C142424586 @default.
• W2793173935 hasConcept C143065580 @default.
• W2793173935 hasConcept C143998085 @default.
• W2793173935 hasConcept C167135981 @default.
• W2793173935 hasConcept C207583985 @default.
• W2793173935 hasConcept C2776694085 @default.
• W2793173935 hasConcept C2777506169 @default.
• W2793173935 hasConcept C2778087573 @default.
• W2793173935 hasConcept C2779438470 @default.
• W2793173935 hasConcept C2780739268 @default.
• W2793173935 hasConcept C2781197716 @default.
• W2793173935 hasConcept C2909325608 @default.
• W2793173935 hasConcept C55493867 @default.
• W2793173935 hasConcept C71924100 @default.
• W2793173935 hasConcept C86803240 @default.
• W2793173935 hasConcept C87355193 @default.
• W2793173935 hasConceptScore W2793173935C104317684 @default.
• W2793173935 hasConceptScore W2793173935C121608353 @default.
• W2793173935 hasConceptScore W2793173935C126322002 @default.

• next